title: Registration system for growth hormone (GH) treatment with standardized immunoreactive GH values in Japan.
abstract: The Foundation for Growth Science has been controlling the use of GH by its registration system, which includes a scoring system for the eligibility for GH treatment according to the diagnostic criteria for GH deficiency (GHD) established by the Study Group for Hypothalamo-pituitary Disorder of the Ministry of Health and Welfare. Until 1995, 28,876 patients with GHD (19,432 boys and 9,444 girls) had been registered as eligible for GH treatment. The number of patients registered in a year increased gradually till 1990 due to the unlimited hGH supply by recombinant techniques and the change in the criteria for GH treatment and the number registered became stable after 1990. The frequency of GH-treated patients is calculated to be 55.2/100,000 persons (72.2/100,000 in boys and 37.1/100,000 in girls) in patients born between 1960 and 1990. The highest frequency was 148.4/100,000 persons (191.7/ 100,000 boys and 103.7/100,000 girls) in 1981, when 2,278 patients (1,508 boys and 770 girls) were born. Eligibility for GH treatment is assessed according to the scoring system which is basically dependent on peak GH values in provocation tests so that standardization of GH values measured with the various commercial GH kits is required to avoid inequality of patients' access to the treatment. In samples obtained by GRF test in 10 normal volunteers, hGH was measured with seven human GH (hGH) kits at a laboratory center. Since the RIA value has been used historically for the diagnosis of GHD, the mean of two RIA measurements was selected as the basis for the standardization procedure and the linear regression formula was used for each hGH kit. After the freely available supply of hGH obtained by recombinant DNA techniques, the role of the Foundation for Growth Science has changed to avoid hGH abuse. Even with this regulation, the frequency of registered patients may indicate a tendency to GH overuse.
authors.affiliation: The Foundation for Growth Science, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Tanaka
authors.forename: K
authors.initials: K
authors.lastname: Takano
authors.forename: K
authors.initials: K
authors.lastname: Hanew
authors.forename: Y
authors.initials: Y
authors.lastname: Nishi
authors.forename: Y
authors.initials: Y
authors.lastname: Igarashi
authors.forename: T
authors.initials: T
authors.lastname: Hirano
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: K
authors.initials: K
authors.lastname: Tachibana
authors.forename: S
authors.initials: S
authors.lastname: Yokoya
authors.forename: K
authors.initials: K
authors.lastname: Fujieda
authors.forename: A
authors.initials: A
authors.lastname: Shimatsu
authors.forename: N
authors.initials: N
authors.lastname: Hizuka
authors.forename: T
authors.initials: T
authors.lastname: Tsushima
authors.forename: M
authors.initials: M
authors.lastname: Irie
mesh_terms: D002648:Child; D002675:Child, Preschool; D005260:Female; D006130:Growth Disorders / Q000097:blood / Q000188:drug therapy; D019382:Human Growth Hormone / Q000032:analysis* / Q000627:therapeutic use*; D006801:Humans; D007564:Japan; D008297:Male; D011863:Radioimmunoassay; D011933:Reagent Kits, Diagnostic; D012016:Reference Values; D012042:Registries
chemical_list: D011933:Reagent Kits, Diagnostic; D019382:Human Growth Hormone